on Moderna, Inc. (NASDAQ:MRNA)
Moderna to Present mRNA Therapeutics Data at ESMO Congress 2025
Moderna, Inc. (NASDAQ: MRNA) has announced that three abstracts on its investigational mRNA therapeutics will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin. The event will take place from October 17 to 21. Key presentations will highlight Moderna's mRNA-4359, a therapy designed to trigger T-cell immune responses against tumors, and intismeran autogene (V940/mRNA-4157), co-developed with Merck.
A mini oral presentation, scheduled for October 17, will delve into clinical outcomes of mRNA-4359 when combined with pembrolizumab in treating resistant melanoma. Additionally, two poster presentations will explore intismeran autogene's efficacy in bladder cancer and as a first-line therapy for advanced melanoma.
Moderna will also host an analyst event during the ESMO Congress to provide further insights into their developments.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Moderna, Inc. news